EMVision Medical Devices (EMV) H2 2025 earnings summary

Executive summary

• Transitioned from R&D to preparing for market access and commercialisation, with significant progress in clinical validation and regulatory engagement for portable brain scanners targeting stroke and traumatic brain injury.

• Released strong multi-site study results for the emu™ scanner, showing high sensitivity and specificity for stroke detection, supporting pivotal trial progression.

• Expanded global clinical collaborations and secured major government grants to accelerate commercialisation and rural healthcare integration.

• Advanced development and field testing of the ultra-light First Responder device, with multiple pre-hospital studies scheduled.

• Expanded manufacturing capabilities and strengthened the board with new expertise in hospital operations and commercialisation.

Financial highlights

• Revenue and income from ordinary activities decreased 51% year-over-year to $5.63 million, mainly due to lower grant and R&D tax incentive income.

• Net loss after tax increased 259% year-over-year to $9.81 million, reflecting higher R&D and operational expenses.

• Total administration, employee, and R&D costs rose 5.9% to $12.91 million, driven by expanded clinical trials and device manufacturing.

• Net operating cash outflows increased to $7.84 million from $5.99 million, with lower grant receipts and higher trial activity.

• Cash balance at year-end was $10.46 million, down from $18.60 million the prior year.

Outlook and guidance

• Six clinical studies planned for the coming year across both commercial devices, including completion of the emu™ pivotal trial.

• Continued focus on expanding stroke and traumatic brain injury indications and leveraging grant funding for commercialisation.

• Ongoing execution of market engagement strategy with leading clinicians and institutions globally.